Welcome to our dedicated page for Apellis Pharmace SEC filings (Ticker: APLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apellis Pharmaceuticals, Inc. filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company with common stock registered under the Exchange Act. The company’s 8-K reports cover product revenue disclosures for SYFOVRE and EMPAVELI, cash and financial-condition updates, and material agreements related to collaborations, royalty arrangements, financing consents, and strategic transaction activity.
Apellis filings also record governance and compensation matters, including board appointments, director compensation, executive separation and retention plans, and related equity-award provisions. These documents disclose formal corporate actions, capital-structure references, material-event reporting, and the company’s public-company obligations as a Delaware issuer.
Apellis Pharmaceuticals' Chief Scientific Officer, Pascal Deschatelets, reported a small insider stock sale. On January 13, 2026, he sold 2,277 shares of Apellis common stock at a price of $22.1872 per share. According to the footnote, these shares were sold solely to cover tax withholding on Restricted Stock Units that were released on January 12, 2026.
After this transaction, Deschatelets beneficially owned 1,158,219 shares of Apellis common stock in direct form. The filing is made as a Form 4 by a single reporting person in his capacity as Chief Scientific Officer.
Apellis Pharmaceuticals CEO Cedric Francois, who also serves as a director, reported a sale of common stock. On January 13, 2026, he sold 10,186 shares of Apellis common stock at a price of $22.1872 per share, leaving him with 321,419 shares held directly. The filing explains that this sale was made to cover tax withholding on restricted stock units that were released on January 12, 2026.
In addition to his direct holdings, the filing lists indirect holdings in several trusts: 307,946 shares held by The Cedric Francois Irrevocable Trust of 2023 - 2, 472,065 shares held by The Cedric Francois Irrevocable Trust of 2023, 300,000 shares held by The Francois Grossi Trust, and 234,411 shares held by The Francois-DuBois Educational Trust. For each of these trusts, the filing states that Francois disclaims beneficial ownership of the shares except to the extent of his pecuniary interest.
Apellis Pharmaceuticals' Chief Technical Officer Nur Nicholson reported a sale of company stock. On January 13, 2026, Nicholson sold 2,618 shares of Apellis common stock at a price of $22.1872 per share. According to the disclosure, these shares were sold to cover tax withholding on Restricted Stock Units that were released on January 12, 2026, meaning the transaction was tied to an equity award rather than an open-market discretionary sale of the full grant.
After this tax-related sale, Nicholson beneficially owned 81,046 shares of Apellis common stock in direct ownership. The filing is made as a Form 4, which reports changes in insider ownership for officers, and confirms Nicholson’s role as Chief Technical Officer of Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals Chief Financial Officer Timothy Sullivan reported a sale of company common stock. On January 13, 2026, he sold 3,856 shares at a price of $22.1872 per share, a transaction code "S". According to the footnotes, these shares were sold solely to cover tax withholding related to restricted stock units that were released on January 12, 2026, rather than as a discretionary open-market sale.
After this transaction, Sullivan directly held 107,080 shares of Apellis common stock. In addition, 60,396 shares are held indirectly by The Timothy E Sullivan Irrevocable Trust of 2023. A separate footnote explains that Patrick O. Collins is the trustee of this trust and that Sullivan disclaims beneficial ownership of those trust-held shares except to the extent of his pecuniary interest in them.
Apellis Pharmaceuticals General Counsel David O. Watson reported a small open-market sale of company stock. On January 13, 2026, he sold 5,780 shares of common stock at a price of $22.1872 per share under transaction code "S". The footnotes explain this sale was made to cover tax withholding on restricted stock units that were released on January 12, 2026.
After the sale, Watson beneficially owned 98,838 Apellis common shares directly. He also had indirect holdings of 10,000 shares in a custodial account for his minor children and 50,136 shares held by The David O. Watson Irrevocable Trust of 2023, where he disclaims beneficial ownership except for any pecuniary interest.
Apellis Pharmaceuticals has a shareholder planning to sell 2618 shares of common stock under Rule 144. The shares are to be sold through Fidelity Brokerage Services LLC, with an aggregate market value of 58086.09, on or about 01/13/2026 on the NASDAQ exchange. The filing notes that 126525218 shares of the issuer’s stock are outstanding. The 2618 shares being sold were acquired on 01/12/2026 through restricted stock vesting from the issuer as compensation, indicating they are newly vested shares now eligible for resale under Rule 144.
Apellis Pharmaceuticals shareholder files notice to sell restricted stock. A holder of Apellis common shares filed a Form 144 to potentially sell 873 shares of common stock through Fidelity Brokerage Services LLC on or about 01/13/2026, with the shares listed on NASDAQ. The shares have an aggregate market value of $19,369.43, compared with 126,525,218 common shares outstanding. These securities were acquired on 01/12/2026 via restricted stock vesting from the issuer as compensation, with payment also dated 01/12/2026.
Apellis Pharmaceuticals insider David O. Watson filed a notice of proposed sale of 5,780 common shares under Rule 144. The shares are expected to be sold through Fidelity Brokerage Services on NASDAQ around 01/13/2026, with an indicated aggregate market value of 128,242.01. The filing notes that 126,525,218 common shares were outstanding.
The 5,780 shares were acquired on 01/12/2026 through restricted stock vesting from the issuer as compensation. The notice also lists prior sales by Watson over the past three months, including three separate sales of 5,000 common shares each on 10/16/2025, 11/17/2025, and 12/16/2025 with gross proceeds of 126,100.00, 100,300.00, and 122,450.00, respectively.
A shareholder filed a Rule 144 notice to sell 1,780 shares of common stock through Fidelity Brokerage Services LLC on or about 01/13/2026, with an indicated aggregate market value of 39,493.22. The planned sale is listed for trading on NASDAQ, and the table notes that there were 126,525,218 shares outstanding when the form was prepared.
The shares to be sold were acquired on 01/12/2026 via a restricted stock vesting transaction from the issuer, described as compensation. The signer represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
A shareholder of APLS filed a notice of proposed sale of common stock under Rule 144. The filing covers the potential sale of 2,277 common shares through Fidelity Brokerage Services LLC, with an aggregate market value of $50,520.25, when 126,525,218 shares of the issuer’s common stock were outstanding. The shares to be sold were acquired from the issuer as restricted stock vesting on 01/12/2026 as compensation, with an approximate intended sale date of 01/13/2026 on the NASDAQ exchange.